Lung, Urothelial Cancers: Phase 1b/2 Trial of Avelumab With Chemotherapy

Share this content:
Researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with NSCLC or urothelial cancer.
Researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with NSCLC or urothelial cancer.

Title: A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies1

Principal Investigators: None listed.

Description: For this open-label, non-randomized phase 1b/2 trial (ClinicalTrials.gov Identifier: NCT03317496), researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with non–small cell lung cancer (NSCLC) or urothelial cancer.

Patients with NSCLC (cohort A1) will receive pemetrexed, carboplatin, and avelumab; all participants will have advanced non-squamous disease. Patients with urothelial cancer (cohort A2) will receive gemcitabine, cisplatin, and avelumab.

The primary outcomes of the phase 1b part are the number of patients with dose-limiting toxicities and the confirmed objective response rate. Secondary outcomes include progression-free survival, duration of response, and overall survival.

The estimated enrollment is 80 patients.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT03317496.

This study is sponsored by Pfizer.

Reference

  1. Clinicaltrials.gov. Safety and efficacy study of avelumab plus chemotherapy with or without other anti-cancer immunotherapy agents in patients with advanced malignancies.  NCT03317496. https://clinicaltrials.gov/ct2/show/NCT03317496. Accessed January 26, 2018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs